JPMORGAN CHASE & CO - 31 Dec 2024 SCHEDULE 13G Report for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC)

Filing Manager: JPMORGAN CHASE & CO
Reporting Manager: JPMORGAN CHASE & CO.
Security: Revance Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: RVNC
Shares outstanding: 105,307,981 shares
Disclosed Ownership: 5,686,631 shares
Ownership: 5.4%
Form type: SCHEDULE 13G
Filing time: 11 Feb 2025, 12:16:38 UTC
Date of event: 31 Dec 2024
Next filing: 06 Mar 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
JPMORGAN CHASE & CO.	5.4%	5,686,631	5,686,631	0	Rachel Tsvaygoft	Vice President